The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Results from the Phase III Vivacity-MG3 trial show that Imaavy provides more consistent disease control than other approved ...